Nunn-Thompson C L, Simon P A
Department of Pharmacy Practice, College of Pharmacy, University of Illinois, Chicago 60612.
Clin Pharm. 1989 Oct;8(10):710-20.
Nicotine dependence and the role of various pharmacotherapeutic adjuncts in the medical management of nicotine withdrawal and smoking cessation are reviewed. Nicotine has been shown to be the drug in tobacco that causes addiction. The nicotine withdrawal syndrome is primarily characterized by craving, irritability, frustration, anger, anxiety, poor concentration, restlessness, weight gain, and decreased heart rate. Pharmacotherapeutic interventions can be classified into four groups: therapy that (1) replaces nicotine, (2) antagonizes nicotine, (3) provides symptomatic treatment for nicotine withdrawal, and (4) deters smoking. Nicotine replacement therapy with nicotine polacrilex gum has had minimal effect on increasing-smoking cessation among patients seen in a general medical practice setting. It is most effective in nicotine dependent smokers when it is used concomitantly with behavioral or psychological counseling. Nicotine antagonist therapy with mecamylamine may be useful in recalcitrant cases of nicotine dependence. Clonidine, in both oral and transdermal forms, has been shown to be effective for reduction of symptoms and craving associated with smoking cessation. Research on using the tricyclic antidepressants imipramine and doxepin to promote smoking cessation by reducing withdrawal symptoms is in its preliminary phases. Lobeline, an alkaloid with effects similar to those of nicotine, is an FDA Category III drug (i.e., safe, but of unknown efficacy) and is available without prescription. Silver acetate chewing gum deters smoking by producing an unpleasant metallic taste on concomitant ingestion of the agent and tobacco. It is an FDA Category III drug and is available without prescription. Drugs used in therapy of nicotine withdrawal include nicotine replacements, nicotine antagonists, agents to lessen the symptoms of withdrawal, and smoking deterrents. None of the drugs is completely effective. Successful drug use for smoking cessation involves consideration of the psychological, as well as physiological, aspects of nicotine addiction.
本文综述了尼古丁依赖以及各种药物辅助治疗在尼古丁戒断和戒烟医学管理中的作用。研究表明,尼古丁是烟草中导致成瘾的物质。尼古丁戒断综合征的主要特征包括渴望、易怒、沮丧、愤怒、焦虑、注意力不集中、坐立不安、体重增加和心率下降。药物治疗干预可分为四类:(1)替代尼古丁的疗法;(2)拮抗尼古丁的疗法;(3)针对尼古丁戒断提供对症治疗的疗法;(4)阻止吸烟的疗法。在普通医疗环境中,使用尼古丁咀嚼胶进行尼古丁替代疗法对增加戒烟率的效果甚微。当与行为或心理咨询同时使用时,它对尼古丁依赖吸烟者最为有效。使用美加明进行尼古丁拮抗疗法可能对难治性尼古丁依赖病例有用。已证明口服和透皮形式的可乐定对减轻与戒烟相关的症状和渴望有效。关于使用三环类抗抑郁药丙咪嗪和多塞平通过减轻戒断症状来促进戒烟的研究尚处于初步阶段。洛贝林是一种生物碱,其作用与尼古丁相似,是美国食品药品监督管理局(FDA)的III类药物(即安全但疗效未知),无需处方即可获得。醋酸银口香糖通过在同时摄入该药物和烟草时产生不愉快的金属味来阻止吸烟。它是FDA的III类药物,无需处方即可获得。用于治疗尼古丁戒断的药物包括尼古丁替代品、尼古丁拮抗剂、减轻戒断症状的药物和阻止吸烟的药物。没有一种药物是完全有效的。成功使用药物戒烟需要考虑尼古丁成瘾的心理和生理方面。